Top

Targeted Oncology

Published in:

Open Access 01-08-2019 | Kidney Cancer | Systematic Review

Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data

Authors: Michael Moran, Dana Nickens, Katherine Adcock, Meg Bennetts, Arial Desscan, Natalie Charnley, Kate Fife

Published in: Targeted Oncology | Issue 4/2019

Abstract

Background

Randomized controlled trials (RCTs) have stringent inclusion criteria and may not fully represent patients seen in everyday clinical practice. Real-world data (RWD) can provide supportive evidence for the effectiveness of medical interventions in more heterogeneous populations than RCTs. Sunitinib is a widely used first-line treatment for patients with metastatic renal cell carcinoma (mRCC).

Objective

This is the first comprehensive meta-analysis to evaluate the efficacy of sunitinib using the novel approach of combining RCTs and RWD.

Methods

RCTs and RWD studies published between 2000 and 2017 were identified from PubMed, Ovid, MEDLINE, and EMBASE. Eligible studies contained a cohort of ≥ 50 adult patients with mRCC receiving first-line sunitinib treatment. The meta-analysis combined RWD and RCT treatment groups, adjusting for data type (RCT or RWD). Recorded outcomes were median progression-free survival (mPFS), median overall survival (mOS), and objective response rate (ORR). Publication bias was assessed via review of funnel plots for each outcome measure. A random effects model to account for study heterogeneity was applied to each endpoint. Sensitivity analyses evaluated the robustness of the overall estimates.

Results

Of the 3611 studies identified through medical database searches, 22 (15 RWD studies, 7 RCTs) met eligibility criteria and were analyzed. mPFS (18 studies), mOS (19 studies), and ORR (15 studies) were reported for aggregate measures based on 4815, 5321, and 4183 patients, respectively. Reported mPFS (RWD, 7.5–11.0 months; RCTs, 5.6–15.1 months) and ORR data (RWD, 14.0–34.6%; RCTs, 18.8–46.9%) were consistent with the overall confidence estimates (95% confidence interval [CI]) of 9.3 (8.6–10.2) months and 27.9% (24.2–32.0), respectively. Reported mOS showed greater variation in RWD (6.8–33.2 months) compared with RCTs (21.8–31.5 months), with an overall confidence estimate (95% CI) of 23.0 (19.2–27.6) months. Inspection of funnel plots and sensitivity analyses indicated that there was no publication bias for any efficacy endpoint. Sensitivity analyses showed no evidence of lack of robustness for mPFS, mOS, or ORR. Interpretation of these results is limited by differences in trial design, cohort characteristics, and missing data.

Conclusions

This novel, comprehensive meta-analysis validates sunitinib as an effective first-line treatment for patients with mRCC in both RCTs and everyday clinical practice. The methodology provides a framework for future analyses combining data from RCTs and RWD.

Available only for authorised users

Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327–37.PubMed

Maynard MA, Ohh M. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer. Am J Nephrol. 2004;24:1–13. https://doi.org/10.1159/000075346.CrossRefPubMed

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. https://doi.org/10.3322/caac.21492.CrossRefPubMed

Dabestani S, Thorstenson A, Lindblad P, Harmenberg U, Ljungberg B, Lundstam S. Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. World J Urol. 2016;34:1081–6. https://doi.org/10.1007/s00345-016-1773-y.CrossRefPubMed

The American Cancer Society. Survival rates for kidney cancer by stage. https://www.cancer.org/cancer/kidney-cancer/detection-diagnosis-staging/survival-rates.html Accessed Dec 2018.

Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688–96. https://doi.org/10.1200/JCO.1995.13.3.688.CrossRefPubMed

Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol. 1993;11:1368–75. https://doi.org/10.1200/JCO.1993.11.7.1368.CrossRefPubMed

Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16–24. https://doi.org/10.1200/JCO.2005.02.2574.CrossRefPubMed

Motzer RJ, Michaelson MD, Rosenberg J, Bukowski RM, Curti BD, George DJ, et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol. 2007;178:1883–7. https://doi.org/10.1016/j.juro.2007.07.030.CrossRefPubMed

10.

Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516–24. https://doi.org/10.1001/jama.295.21.2516.CrossRefPubMed

11.

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584–90. https://doi.org/10.1200/JCO.2008.20.1293.CrossRefPubMedPubMedCentral

12.

Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, et al. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncol. 2018;19:451–60. https://doi.org/10.1016/S1470-2045(18)30107-4.CrossRefPubMed

13.

Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277–90. https://doi.org/10.1056/NEJMoa1712126.CrossRefPubMedPubMedCentral

14.

Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103–15. https://doi.org/10.1056/NEJMoa1816047.CrossRefPubMedPubMedCentral

15.

Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–27. https://doi.org/10.1056/NEJMoa1816714.CrossRefPubMed

16.

Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):706–20. https://doi.org/10.1093/annonc/mdz056.CrossRefPubMed

17.

European Association of Urology. Renal Cell Carcinoma Guidelines. 2019. https://uroweb.org/guideline/renal-cell-carcinoma/. Accessed May 2019.

18.

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer. Version 3. 2019. https://www.nccn.org/professionals/physician_gls/default.aspx#site. Accessed May 2019.

19.

Zarrabi K, Fang C, Wu S. New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy. J Hematol Oncol. 2017;10:38. https://doi.org/10.1186/s13045-016-0374-y.CrossRefPubMedPubMedCentral

20.

Goebell PJ, Staehler M, Muller L, Nusch A, Scheffler M, Sauer A, et al. Changes in treatment reality and survival of patients with advanced clear cell renal cell carcinoma—analyses from the german clinical RCC-registry. Clin Genitourin Cancer. 2018. https://doi.org/10.1016/j.clgc.2018.06.006.CrossRefPubMed

21.

Kaptchuk TJ. The double-blind, randomized, placebo-controlled trial: gold standard or golden calf? J Clin Epidemiol. 2001;54:541–9.CrossRefPubMed

22.

Mitchell AP, Harrison MR, Walker MS, George DJ, Abernethy AP, Hirsch BR. Clinical trial participants with metastatic renal cell carcinoma differ from patients treated in real-world practice. J Oncol Pract. 2015;11:491–7. https://doi.org/10.1200/JOP.2015.004929.CrossRefPubMed

23.

Ramamoorthy A, Knepper TC, Merenda C, Mendoza M, McLeod HL, Bull J, et al. demographic composition of select oncologic new molecular entities approved by the FDA between 2008 and 2017. Clin Pharmacol Ther. 2018;104:940–8. https://doi.org/10.1002/cpt.1180.CrossRefPubMedPubMedCentral

24.

Elting LS, Cooksley C, Bekele BN, Frumovitz M, Avritscher EB, Sun C, et al. Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer. 2006;106:2452–8. https://doi.org/10.1002/cncr.21907.CrossRefPubMed

25.

Rothwell PM. Commentary: external validity of results of randomized trials: disentangling a complex concept. Int J Epidemiol. 2010;39:94–6. https://doi.org/10.1093/ije/dyp305.CrossRefPubMed

26.

Dekkers OM, von Elm E, Algra A, Romijn JA, Vandenbroucke JP. How to assess the external validity of therapeutic trials: a conceptual approach. Int J Epidemiol. 2010;39:89–94. https://doi.org/10.1093/ije/dyp174.CrossRefPubMed

27.

Argyropulo-Palmer M, Jenkins A, Theti DS, Larkin J, Montgomery D. Sunitinib in metastatic renal cell carcinoma: a systematic review of UK real world data. Front Oncol. 2015;5:195. https://doi.org/10.3389/fonc.2015.00195.CrossRefPubMedPubMedCentral

28.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:e1–34. https://doi.org/10.1016/j.jclinepi.2009.06.006.CrossRefPubMed

29.

Morrison A, Polisena J, Husereau D, Moulton K, Clark M, Fiander M, et al. The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies. Int J Technol Assess Health Care. 2012;28:138–44. https://doi.org/10.1017/S0266462312000086.CrossRefPubMed

30.

Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016;17:378–88. https://doi.org/10.1016/S1470-2045(15)00515-X.CrossRefPubMedPubMedCentral

31.

Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol. 2017;35:591–7. https://doi.org/10.1200/JCO.2016.70.7398.CrossRefPubMed

32.

Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32:2765–72. https://doi.org/10.1200/JCO.2013.54.6911.CrossRefPubMedPubMedCentral

33.

Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369:722–31. https://doi.org/10.1056/NEJMoa1303989.CrossRefPubMed

34.

Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol. 2012;30:1371–7. https://doi.org/10.1200/JCO.2011.36.4133.CrossRefPubMed

35.

Rini BI, Stenzl A, Zdrojowy R, Kogan M, Shkolnik M, Oudard S, et al. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17:1599–611. https://doi.org/10.1016/S1470-2045(16)30408-9.CrossRefPubMed

36.

Bamias A, Karadimou A, Lampaki S, Lainakis G, Malettou L, Timotheadou E, et al. Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model. BMC Cancer. 2010;10:45. https://doi.org/10.1186/1471-2407-10-45.CrossRefPubMedPubMedCentral

37.

Day D, Kanjanapan Y, Kwan E, Yip D, Lawrentschuk N, Andrews M, et al. Patterns of care for metastatic renal cell carcinoma in Australia. BJU Int. 2015;116(Suppl 3):36–41. https://doi.org/10.1111/bju.13176.CrossRefPubMed

38.

De Giorgi U, Scarpi E, Sacco C, Aieta M, Lo Re G, Sava T, et al. Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis. Clin Genitourin Cancer. 2014;12:182–9. https://doi.org/10.1016/j.clgc.2013.11.005.CrossRefPubMed

39.

De Groot S, Sleijfer S, Redekop WK, Oosterwijk E, Haanen JB, Kiemeney LA, et al. Variation in use of targeted therapies for metastatic renal cell carcinoma: results from a Dutch population-based registry. BMC Cancer. 2016;16:364. https://doi.org/10.1186/s12885-016-2395-x.CrossRefPubMedPubMedCentral

40.

Heng DY, Chi KN, Murray N, Jin T, Garcia JA, Bukowski RM, et al. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer. 2009;115:776–83. https://doi.org/10.1002/cncr.24051.CrossRefPubMed

41.

Lalani AA, Li H, Heng DYC, Wood L, Kalirai A, Bjarnason GA, et al. First-line sunitinib or pazopanib in metastatic renal cell carcinoma: the Canadian experience. Can Urol Assoc J. 2017;11:112–7. https://doi.org/10.5489/cuaj.4398.CrossRefPubMedPubMedCentral

42.

Maroun R, Fleury L, Nachbaur G, Maunoury F, Vanhille JL, Durand-Zaleski I. Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database. Curr Med Res Opin. 2017;33:1755–62. https://doi.org/10.1080/03007995.2017.1360850.CrossRefPubMed

43.

Miyake H, Miyazaki A, Harada K, Fujisawa M. Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan. Med Oncol. 2014;31:978. https://doi.org/10.1007/s12032-014-0978-4.CrossRefPubMed

44.

Noize P, Grelaud A, Bay JO, Chevreau C, Gross-Goupil M, Culine S, et al. Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study. Pharmacoepidemiol Drug Saf. 2017;26:1561–9. https://doi.org/10.1002/pds.4228.CrossRefPubMed

45.

Pan X, Huang H, Huang Y, Liu B, Cui X, Gan S, et al. Sunitinib dosing schedule 2/1 improves tolerability, efficacy, and health-related quality of life in Chinese patients with metastatic renal cell carcinoma. Urol Oncol. 2015;33(268):e9–15. https://doi.org/10.1016/j.urolonc.2015.03.008.CrossRef

46.

Poprach A, Lakomy R, Bortlicek Z, Melichar B, Pavlik T, Slaby O, et al. Efficacy of sunitinib in elderly patients with metastatic renal cell carcinoma: data from real-world clinical practice. Drugs Aging. 2016;33:655–63. https://doi.org/10.1007/s40266-016-0390-1.CrossRefPubMed

47.

Schnadig ID, Hutson TE, Chung H, Dhanda R, Halm M, Forsyth M, et al. Dosing patterns, toxicity, and outcomes in patients treated with first-line sunitinib for advanced renal cell carcinoma in community-based practices. Clin Genitourin Cancer. 2014;12:413–21. https://doi.org/10.1016/j.clgc.2014.06.015.CrossRefPubMed

48.

Sheng X, Chi Z, Cui C, Si L, Li S, Tang B, et al. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis. Oncotarget. 2016;7:27044–54. https://doi.org/10.18632/oncotarget.7395.CrossRefPubMedPubMedCentral

49.

Tan HS, Li H, Hong YW, Toh CK, Wong A, Lopes G, et al. Efficacy and safety of an attenuated-dose sunitinib regimen in metastatic renal cell carcinoma: results from a prospective registry in singapore. Clin Genitourin Cancer. 2015;13:e285–95. https://doi.org/10.1016/j.clgc.2014.11.004.CrossRefPubMed

50.

Zhang HL, Sheng XN, Li XS, Wang HK, Chi ZH, He ZS, et al. Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors. BMC Cancer. 2017;17:16. https://doi.org/10.1186/s12885-016-3016-4.CrossRefPubMedPubMedCentral

51.

Ruiz-Morales JM, Swierkowski M, Wells JC, Fraccon AP, Pasini F, Donskov F, et al. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur J Cancer. 2016;65:102–8. https://doi.org/10.1016/j.ejca.2016.06.016.CrossRefPubMed

52.

Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, et al. Real-world survival outcomes and prognostic factors among patients receiving first targeted therapy for advanced renal cell carcinoma: a SEER-medicare database analysis. Clin Genitourin Cancer. 2017;15:e573–82. https://doi.org/10.1016/j.clgc.2016.12.005.CrossRefPubMed

53.

Pearce W, Raman S, Turner A. Randomised trials in context: practical problems and social aspects of evidence-based medicine and policy. Trials. 2015;16:394. https://doi.org/10.1186/s13063-015-0917-5.CrossRefPubMedPubMedCentral

54.

Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, et al. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. J Immunother Cancer. 2018;6:109. https://doi.org/10.1186/s40425-018-0420-0.CrossRefPubMedPubMedCentral

55.

Fiedler W, Serve H, Dohner H, Schwittay M, Ottmann OG, O’Farrell AM, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood. 2005;105:986–93. https://doi.org/10.1182/blood-2004-05-1846.CrossRefPubMed

56.

Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24:25–35. https://doi.org/10.1200/JCO.2005.02.2194.CrossRefPubMed

57.

Boegemann M, Hubbe M, Thomaidou D, Blackburn S, Bent-Ennakhil N, Wood R, et al. Sunitinib treatment modification in first-line metastatic renal cell carcinoma: analysis of the STAR-TOR registry. Anticancer Res. 2018;38:6413–22. https://doi.org/10.21873/anticanres.13002.CrossRefPubMed

58.

Lee JL, Kim MK, Park I, Ahn JH, Lee DH, Ryoo HM, et al. RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial. Ann Oncol. 2015;26:2300–5. https://doi.org/10.1093/annonc/mdv357.CrossRefPubMed

59.

Fujita T, Hirayama T, Ishii D, Matsumoto K, Yoshida K, Iwamura M. Efficacy and safety of sunitinib in elderly patients with advanced renal cell carcinoma. Mol Clin Oncol. 2018;9:394–8. https://doi.org/10.3892/mco.2018.1684.CrossRefPubMedPubMedCentral

60.

Miyake H, Aki R, Matsushita Y, Tamura K, Motoyama D, Ito T, et al. Significance of age in Japanese patients receiving sunitinib as first-line systemic therapy for metastatic renal cell carcinoma: comparative assessment of efficacy and safety between patients aged < 75 and >/=75 years. Anticancer Res. 2018;38:3593–9. https://doi.org/10.21873/anticanres.12633.CrossRefPubMed

61.

Hutson TE, Bukowski RM, Rini BI, Gore ME, Larkin JM, Figlin RA, et al. Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. Br J Cancer. 2014;110:1125–32. https://doi.org/10.1038/bjc.2013.832.CrossRefPubMedPubMedCentral

62.

Guo J, Jin J, Oya M, Uemura H, Takahashi S, Tatsugami K, et al. Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial. J Hematol Oncol. 2018;11:69. https://doi.org/10.1186/s13045-018-0617-1.CrossRefPubMedPubMedCentral

63.

Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, et al. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. Br J Cancer. 2015;113:12–9. https://doi.org/10.1038/bjc.2015.196.CrossRefPubMedPubMedCentral

64.

Heng DY, Choueiri TK, Rini BI, Lee J, Yuasa T, Pal SK, et al. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol. 2014;25:149–54. https://doi.org/10.1093/annonc/mdt492.CrossRefPubMedPubMedCentral

65.

Marschner N, Staehler M, Muller L, Nusch A, Harde J, Koska M, et al. Survival of patients with advanced or metastatic renal cell carcinoma in routine practice differs from that in clinical trials-analyses from the german clinical RCC registry. Clin Genitourin Cancer. 2017;15:e209–15. https://doi.org/10.1016/j.clgc.2016.08.022.CrossRefPubMed

66.

Nieder C, Syed MA, Dalhaug A, Pawinski A, Norum J. Eligibility for phase 3 clinical trials of systemic therapy in real-world patients with metastatic renal cell cancer managed in a rural region. Med Oncol. 2017;34:149. https://doi.org/10.1007/s12032-017-1002-6.CrossRefPubMed

67.

Fernandez-Pello S, Hofmann F, Tahbaz R, Marconi L, Lam TB, Albiges L, et al. A systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma. Eur Urol. 2017;71:426–36. https://doi.org/10.1016/j.eururo.2016.11.020.CrossRefPubMed

Title: Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data
Authors: Michael Moran
Dana Nickens
Katherine Adcock
Meg Bennetts
Arial Desscan
Natalie Charnley
Kate Fife
Publication date: 01-08-2019
Publisher: Springer International Publishing
Keywords: Kidney Cancer
Kidney Cancer
Kidney Cancer
Sunitinib
Published in: Targeted Oncology / Issue 4/2019
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-019-00653-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2019

Relative Efficacy of Systemic Treatments for Patients with Advanced Hepatocellular Carcinoma According to Viral Status: A Systematic Review and Network Meta-Analysis

Epidermal Growth Factor Receptor (EGFR)–Tyrosine Kinase Inhibitors (TKIs) Combined with Chemotherapy Delay Brain Metastasis in Patients with EGFR-Mutant Lung Adenocarcinoma

Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib

A Monoclonal Antibody Against β1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma

Correction to: Epidermal Growth Factor Receptor (EGFR)–Tyrosine Kinase Inhibitors (TKIs) Combined with Chemotherapy Delay Brain Metastasis in Patients with EGFR‑Mutant Lung Adenocarcinoma

Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient

Keynote webinar | Spotlight on antibody–drug conjugates in cancer